Literature DB >> 20616742

The early interferon alpha subtype response in infant macaques infected orally with SIV.

Juliet Easlick1, Richard Szubin, Samantha Lantz, Nicole Baumgarth, Kristina Abel.   

Abstract

Type I interferons play an important role in the early defense against viral and other pathogens. These innate responses are also critically important in shaping the subsequent adaptive response. Thus, a more thorough knowledge of innate response types and mechanisms will improve our understanding of pathogenesis and guide the development of new therapeutics. Interferon alpha (IFN-alpha) is used clinically in the treatment of HIV and hepatitis C infections. The majority of IFA-alpha therapy is based on a single IFN-alpha subtype, IFN-alpha2. However, IFN-alpha comprises a family of multiple subtypes. The biologic functions of the distinct subtypes and how they relate to disease are poorly understood. The current study developed the tools to distinguish and measure multiple IFN-alpha subtypes on the mRNA level in rhesus macaques that are used widely as an important animal model for human diseases. We were able to identify and measure nine distinct rhesus IFN-alpha subtypes. Furthermore, we could demonstrate that in response to oral pathogenic SIV infection, several IFN-alpha subtypes are rapidly induced in lymphoid but not at oral and gastrointestinal mucosal surfaces. Although each IFN-alpha subtype was induced at distinct levels, their relative expression patterns were identical in all lymphoid tissues examined.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616742      PMCID: PMC2927738          DOI: 10.1097/QAI.0b013e3181e696ca

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  42 in total

1.  Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.

Authors:  Koen K A Van Rompay; Kimberli A Schmidt; Jonathan R Lawson; Raman Singh; Norbert Bischofberger; Marta L Marthas
Journal:  J Infect Dis       Date:  2002-10-29       Impact factor: 5.226

2.  Negative correlation between blood cell counts and serum neopterin concentration in patients with HIV-1 infection.

Authors:  D Fuchs; G M Shearer; R N Boswell; D R Lucey; M Clerici; G Reibnegger; E R Werner; R A Zajac; H Wachter
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

3.  Interferon-kappa, a novel type I interferon expressed in human keratinocytes.

Authors:  D W LaFleur; B Nardelli; T Tsareva; D Mather; P Feng; M Semenuk; K Taylor; M Buergin; D Chinchilla; V Roshke; G Chen; S M Ruben; P M Pitha; T A Coleman; P A Moore
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

4.  Differential expression of human interferon genes.

Authors:  J Hiscott; K Cantell; C Weissmann
Journal:  Nucleic Acids Res       Date:  1984-05-11       Impact factor: 16.971

5.  Differential expression of IFN-alpha subtypes in human PBMC: evaluation of novel real-time PCR assays.

Authors:  S Löseke; E Grage-Griebenow; A Wagner; K Gehlhar; A Bufe
Journal:  J Immunol Methods       Date:  2003-05-01       Impact factor: 2.303

6.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

7.  Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection.

Authors:  M von Sydow; A Sönnerborg; H Gaines; O Strannegård
Journal:  AIDS Res Hum Retroviruses       Date:  1991-04       Impact factor: 2.205

8.  The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection.

Authors:  Kristina Abel; Michelle J Alegria-Hartman; Kristina Rothaeusler; Marta Marthas; Christopher J Miller
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Optimization of methods to assess human mucosal T-cell responses to HIV infection.

Authors:  Barbara L Shacklett; Otto Yang; Mary Ann Hausner; Julie Elliott; Lance Hultin; Charles Price; Marie Fuerst; Jose Matud; Patricia Hultin; Catherine Cox; Javier Ibarrondo; Johnson T Wong; Douglas F Nixon; Peter A Anton; Beth D Jamieson
Journal:  J Immunol Methods       Date:  2003-08       Impact factor: 2.303

10.  The antiviral efficacy of the murine alpha-1 interferon transgene against ocular herpes simplex virus type 1 requires the presence of CD4(+), alpha/beta T-cell receptor-positive T lymphocytes with the capacity to produce gamma interferon.

Authors:  Daniel J J Carr; Sansanee Noisakran
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  14 in total

1.  Induction of IFN-α subtypes and their antiviral activity in mumps virus infection.

Authors:  Maja Markušić; Maja Šantak; Tanja Košutić-Gulija; Mladen Jergović; Renata Jug; Dubravko Forčić
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

2.  High-throughput quantitative real-time polymerase chain reaction array for absolute and relative quantification of rhesus macaque types I, II, and III interferon and their subtypes.

Authors:  Lynnsie M Schramm; Kevin D Kirschman; Melissa Heuer; Aaron A Chen; Daniela Verthelyi; Montserrat Puig; Ronald L Rabin
Journal:  J Interferon Cytokine Res       Date:  2012-07-20       Impact factor: 2.607

3.  Tissue-specific interferon alpha subtype response to SIV infection in brain, spleen, and lung.

Authors:  Luna Alammar Zaritsky; Alicia Dery; Wan Yee Leong; Lucio Gama; Janice E Clements
Journal:  J Interferon Cytokine Res       Date:  2012-10-10       Impact factor: 2.607

4.  Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.

Authors:  Thorsten Demberg; Amelia C Ettinger; Stanley Aladi; Katherine McKinnon; Thea Kuddo; David Venzon; L Jean Patterson; Terry M Phillips; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2011-06-25       Impact factor: 3.641

5.  Enhanced innate antiviral gene expression, IFN-α, and cytolytic responses are predictive of mucosal immune recovery during simian immunodeficiency virus infection.

Authors:  David Verhoeven; Michael D George; William Hu; Angeline T Dang; Zeljka Smit-McBride; Elizabeth Reay; Monica Macal; Anne Fenton; Sumathi Sankaran-Walters; Satya Dandekar
Journal:  J Immunol       Date:  2014-03-07       Impact factor: 5.422

6.  A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.

Authors:  S Miersch; S Kuruganti; M R Walter; S S Sidhu
Journal:  Protein Eng Des Sel       Date:  2017-09-01       Impact factor: 1.650

7.  Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.

Authors:  Edith Jasny; Suzanne Geer; Ines Frank; Panagiotis Vagenas; Meropi Aravantinou; Andres M Salazar; Jeffrey D Lifson; Michael Piatak; Agegnehu Gettie; James L Blanchard; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

Review 8.  Interferons and viruses: an evolutionary arms race of molecular interactions.

Authors:  Hans-Heinrich Hoffmann; William M Schneider; Charles M Rice
Journal:  Trends Immunol       Date:  2015-02-20       Impact factor: 16.687

Review 9.  IFN-α subtypes: distinct biological activities in anti-viral therapy.

Authors:  K Gibbert; J F Schlaak; D Yang; U Dittmer
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIV-infected cynomolgus macaques.

Authors:  Timothée Bruel; Stéphanie Dupuy; Thomas Démoulins; Christine Rogez-Kreuz; Jacques Dutrieux; Aurélien Corneau; Antonio Cosma; Rémi Cheynier; Nathalie Dereuddre-Bosquet; Roger Le Grand; Bruno Vaslin
Journal:  PLoS Pathog       Date:  2014-01-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.